LDR Announces Release Of Its ROI-T TM Transforaminal Approach Implant
LDR, a total spine solution company, announced that it has begun to market its ROI-T™ partial vertebral body replacement device following recent 510(k) clearance from the United States Food and Drug Administration. The ROI-T™ is a transforaminal approach implant with an anatomic shape that conforms to the anterior vertebral body, the minimal width and tapered end of the device facilitating insertion through a small opening.
Osteologix Presents Phase 2 Osteoporosis Data At A Major European Medical Conference
Osteologix, Inc. (OTCBB: OLGX), a specialty pharmaceutical company, announced today that data from a Phase II clinical study of NB S101 (strontium malonate) was presented at the European Calcified Tissue Society's 35th Annual Meeting in Barcelona, Spain.
Study Presented At SpineWeek Finds Plasma Disc Decompression Effective For Contained Cervical Disc Herniation
ArthroCare Corp. (Nasdaq: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced that a study demonstrating the effectiveness of plasma disc decompression (PDD) for treating patients with contained disc herniation was presented from the podium yesterday at SpineWeek 2008 in Geneva.
U.S. Hispanic Women Face Osteoporosis Epidemic
Osteoporosis is a disease that can be crippling, leaving bones brittle, weak and easily broken. There are already some 8 million women in the U.S. who suffer from osteoporosis* and experts say that number could soon skyrocket. She may not quite understand the language yet, or the technology behind the test, but Sandra Ramos knows the importance of a simple heel scan.
A Glass Apart
British scientists are developing a new type of glass that can dissolve and release calcium into the body. This will enable patients to regrow bones and could signal a move away from bone transplants.The porous glass, originally developed at Imperial College is capable of acting as an active template for new bone growth, dissolving in the body without leaving any trace of itself or any toxic chemicals.
Global Study Reveals Differences In Standard Of Care For Osteoporosis Across The World
In a first-of-its-kind study in osteoporosis, one in four women surveyed from Europe, North America, and Australia reported having one or more bone fractures since the age of 45 years. Among women considered to be at high risk for a fracture, only 26% reported use of bone-saving drugs, with use reported significantly less frequently in Europe than in North America and Australia.
Wyeth Receives Approvable Letter From FDA For Bazedoxifene For The Treatment Of Postmenopausal Osteoporosis
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis.
Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits In Ongoing Phase I II Myelofibrosis Study
Incyte Corporation (Nasdaq: INCY) announced the presentation of clinical results from a Phase I/II study of INCB18424, its orally available janus-associated kinase (JAK) inhibitor, in patients with myelofibrosis. Myelofibrosis (MF) is a serious neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms resulting in a significant loss in quality of life and reduced life-span.
Denosumab Osteoporosis Study Meets Primary And All Secondary Bone Mineral Density Endpoints In Alendronate FOSAMAX R Transition Study
Amgen (NASDAQ: AMGN) announced findings from a head-to-head, double blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD).
HIV Patients Suffer More From Osteoporosis
Following the introduction of HAART (Highly Active Antiretroviral Therapy), the survival and quality of life for people infected with the human immunodeficiency virus (HIV-1) have increased in the resource-rich countries. However, with this improved prognosis an increase in long term negative disorders has been observed, namely osteoporosis (the gradual loss of bone mass).